KOSAN Biosciences, Inc.
3832 Bay Center Place
Hayward
California
94545
United States
Tel: 510-732-8400
Fax: 510-732-8401
Website: http://www.kosan.com/
101 articles about KOSAN Biosciences, Inc.
-
Bristol-Myers Squibb Company Completes Acquisition of KOSAN Biosciences, Inc.
6/27/2008
-
Bristol-Myers Squibb Company Completes Tender Offer for KOSAN Biosciences, Inc.
6/26/2008
-
Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of KOSAN Biosciences, Inc.
6/18/2008
-
KOSAN Biosciences, Inc.'s Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial; Data Presented at American Society of Clinical Oncology Show 26% Partial Respons
6/3/2008
-
Bristol-Myers Squibb Company Begins Tender Offer to Acquire KOSAN Biosciences, Inc.
5/30/2008
-
Bristol-Myers Squibb Company to Acquire KOSAN Biosciences, Inc. for $190 Million
5/29/2008
-
KOSAN Biosciences, Inc. Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
5/20/2008
-
KOSAN Biosciences, Inc. Announces Data Presentations at American Society of Clinical Oncology 2008 Annual Meeting
5/14/2008
-
KOSAN Biosciences, Inc. First Quarter 2008 Financial Results
5/2/2008
-
KOSAN Biosciences, Inc. Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
4/25/2008
-
KOSAN Biosciences, Inc. Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents
4/17/2008
-
KOSAN Biosciences, Inc. Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors
4/17/2008
-
KOSAN Biosciences, Inc. Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
4/14/2008
-
KOSAN Biosciences, Inc.'s Board of Directors Appoints New CEO
3/19/2008
-
KOSAN Biosciences, Inc. to Cut 37% of Workforce
3/19/2008
-
KOSAN Biosciences, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
3/3/2008
-
KOSAN Biosciences, Inc. Announces Robert G. Johnson, Jr. Resigns as President and Chief Executive Officer
2/29/2008
-
KOSAN Biosciences, Inc. Announces February 28, 2008 Conference Call
2/8/2008
-
KOSAN Biosciences, Inc. Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
1/15/2008
-
KOSAN Biosciences, Inc. Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
1/4/2008